Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome

STATUS

Recruiting
End date

Jun 30, 2025
participants needed

9
sponsor

Uppsala University

Send

Updated on 19 February 2024

See if I qualify

PCR test

respiratory distress

coronavirus

SARS

cell therapy

cellular therapy

coronavirus infection

acute respiratory distress

acute respiratory syndrome (sars)

Summary

This is an open label, dose escalating safety study of the advanced therapy investigational medicinal product (ATIMP) KI-MSC-PL-205, where patients diagnosed with SARS-CoV-2-induced severe acute respiratory distress syndrome (ARDS), according to the Berlin Definition, and who are on respirator/ventilator (used synonymously in this protocol) support due to respiratory insufficiency with or without concomitant circulatory problems, will be included and treated with a single dose of KI-MSC-PL-205.

Details

Condition	ADULT RESPIRATORY DISTRESS SYNDROME, COVID
Age	18years - 65years
Treatment	Mesenchymal Stromal Stem Cells - KI-MSC-PL-205
Clinical Study Identifier	NCT04447833
Sponsor	Uppsala University
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Willing and able to provide written informed consent prior to performing study procedures (and have given written consent)
	Coronavirus (SARS-CoV-2) infection confirmed by polymerase chain reaction (PCR) test at screening
	Male or female patient aged 18 to 65 years old
	Patient must fulfil the Berlin Definition of severe ARDS within 3 weeks to 48 hours prior to enrolment (Will be assessed once the patient has been admitted to the ICU)
	Patient is on respirator support within 3 weeks to 48 hours prior to enrolment (Will be assessed once the patient has been admitted to the ICU)
	Pregnancy test in blood confirming negative results before enrolment (for women 55 years old)
Exclusion Criteria
	History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study, or influence the results or the patient's ability to participate in the study
	Patients with history of treated blood and/or solid organ malignancy with recurrence within five years prior to dosing of the ATIMP are to be excluded. Patients with history of cervix cancer and non-melanoma skin cancer with recurrence within two years prior to dosing of the ATIMP are to be excluded
	Pregnant or breast feeding female
	Patient with a history of anti-coagulation therapy for other indications that short-term prophylaxis after surgery
	Patients with a history and/ or on-going treatment for entity associated with bleeding disorder or potential risk for bleeding (e.g. inflammatory bowel disease, gastro-esophagitis with or without ulcers, haemophilia and other bleeding disorders, inflammatory musculo-skeletal disease with potential bleeding complications)
	Patients with a history during the latest five years and/or on-going treatment for systemic infection (e.g. Septicaemia due to in vivo foreign body (e.g. stents, catheters, heart valve), tuberculosis, malaria, other opportunistic and parasite infections)
	Prisoner
	Any other irreversible disease or condition for which six-month mortality is estimated to be greater than 50%
	Moderate to severe liver failure (Child-Pugh Score >12)
	Reduced renal function with a creatinine clearance (Cockcroft-Gault Equation) < 45 mL/min/1.73m2
	Severe chronic respiratory disease with a PaCO2 >50 mmHg or the use of home oxygen
	Major trauma in the prior 5 days
	Lung transplant patient
	Patients on ECMO-support
	Patients with a previous history of severe burns
	Documented deep venous thrombosis or pulmonary embolism within past three months
	Known hypersensitivity to DMSO
	Investigator considers the patient unlikely to comply with study procedures, restrictions and requirements

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

coronavirus infection

acute respiratory distress

acute respiratory syndrome (sars)

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome